Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | BACE1 | P56817 | 6/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23274795 | 0.84 | BCHE (0.47) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL6490067 | 0.83 | ACHE (0.46) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL9144135 | 0.82 | ACHE (0.53) | ACHEBACE1BCHECYP1A2CYP3A4 | |
| SCHEMBL9213703 | 0.82 | ACHE (0.53) | ACHEBACE1BCHECYP1A2CYP3A4 | |
| SCHEMBL23274839 | 0.81 | ALDH1A1 (0.50) | ACHEBACE1BCHECYP1A2CYP3A4 | |
| SCHEMBL23274957 | 0.79 | BACE1 (0.42) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL23274847 | 0.78 | RECQL (0.43) | ACHEBACE1BCHE | |
| SCHEMBL4884981 | 0.77 | ACHE (0.54) | ACHEBACE1BCHECYP1A2CYP3A4 | |
| SCHEMBL8603139 | 0.77 | BACE1 (0.50) | ACHEBACE1BCHECYP1A2CYP3A4 | |
| SCHEMBL2676079 | 0.77 | ACHE (0.54) | ACHEBACE1BCHECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | ACHE 2050/4885BACE1 42/4885BCHE 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.